{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dmards/background-information/indications/","result":{"pageContext":{"chapter":{"id":"13df5021-0440-5dfe-b200-6910e116b50b","slug":"indications","fullItemName":"Indications","depth":2,"htmlHeader":"<!-- begin field 8d2b75bc-2d93-4956-85c4-3679d84ced4c --><h2>Indications</h2><!-- end field 8d2b75bc-2d93-4956-85c4-3679d84ced4c -->","summary":"","htmlStringContent":"<!-- begin item 13f8a672-0b37-478e-b857-5f74ee2872f4 --><!-- end item 13f8a672-0b37-478e-b857-5f74ee2872f4 -->","topic":{"id":"493980c0-c660-5bda-b643-f98644c1eff8","topicId":"caed8aa7-f8ba-4a46-9441-92701c2ad78a","topicName":"DMARDs","slug":"dmards","lastRevised":"Last revised in April 2020","chapters":[{"id":"d587cd65-a186-50e3-a192-8d3f3b5c074b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e4b02852-ea41-536a-8ec9-462ecfc95b24","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"189d2086-77a0-57a3-84ed-6f44f1e56879","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ff583a6c-57af-5ded-8488-19039e0cd272","slug":"changes","fullItemName":"Changes"},{"id":"d65ec114-ec65-504e-a69b-b4fef29f3ca6","slug":"update","fullItemName":"Update"}]},{"id":"c02019ed-342b-5aa7-a645-a8c979fa0d56","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0ee8d208-7733-5a7d-928a-41e080d05756","slug":"goals","fullItemName":"Goals"},{"id":"2206fe89-030d-5fec-adf5-ee4a379ff3a0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca18e3ee-b448-5d95-b060-d5ab2e909dd2","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ce5c5664-0c85-52e9-b3d1-835fa7e52c8f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ac9bf99d-b5d4-5d63-8e5c-bb174916417e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2c23a774-3e76-52d5-8316-b8cbe2060151","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"33f76ef2-b579-5b80-985a-587d2f7cbb17","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13df5021-0440-5dfe-b200-6910e116b50b","slug":"indications","fullItemName":"Indications"}]},{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","fullItemName":"Management","slug":"management","subChapters":[{"id":"a22ece65-e42d-59b8-82a9-4633e64a7441","slug":"general-principles-of-managing-dmards","fullItemName":"Scenario: General principles of managing DMARDs"},{"id":"7428c7c0-3189-5d82-8d3c-61151fc43773","slug":"apremilast","fullItemName":"Scenario: Apremilast"},{"id":"c241c22b-6dd4-5334-b240-a532f0f78fd7","slug":"azathioprine","fullItemName":"Scenario: Azathioprine"},{"id":"cff5fc6d-3554-5bf8-832a-c8a089699b6f","slug":"baricitinib","fullItemName":"Scenario: Baricitinib"},{"id":"fc4f9786-0db2-5fcd-a2ca-589807093e6a","slug":"biologics","fullItemName":"Scenario: Biologics"},{"id":"a8c361a4-0693-5e57-a935-24a8383a76ba","slug":"ciclosporin","fullItemName":"Scenario: Ciclosporin"},{"id":"92b93974-10b7-5147-b0cb-e21d187093e4","slug":"cyclophosphamide","fullItemName":"Scenario: Cyclophosphamide"},{"id":"928496d4-4642-55d5-98fe-86bd350c2913","slug":"gold-intramuscular","fullItemName":"Scenario: Gold - intramuscular"},{"id":"bed27174-d641-5a3b-958e-fdb3f1b0c33f","slug":"hydroxychloroquine","fullItemName":"Scenario: Hydroxychloroquine"},{"id":"b87df30d-4917-58a4-84b5-2db454410a88","slug":"leflunomide","fullItemName":"Scenario: Leflunomide"},{"id":"29f64422-8646-5cd9-ab79-c6919331e041","slug":"methotrexate","fullItemName":"Scenario: Methotrexate"},{"id":"c4758020-9fa5-5122-9cd7-c871ebd54d73","slug":"mycophenolate-mofetil-mmf","fullItemName":"Scenario: Mycophenolate mofetil (MMF)"},{"id":"5870b3d5-8b5b-5029-86fa-0f688b740005","slug":"penicillamine","fullItemName":"Scenario: Penicillamine"},{"id":"7b2bca14-9fd5-55c7-9a3f-bb044a5c53cb","slug":"sulfasalazine","fullItemName":"Scenario: Sulfasalazine"},{"id":"4fddf07b-12b6-51d6-93db-59bb536a2db1","slug":"tacrolimus","fullItemName":"Scenario: Tacrolimus"},{"id":"1dcd6206-8d6f-548c-a253-fc19d5deb6e7","slug":"tofacitinib","fullItemName":"Scenario: Tofacitinib"},{"id":"6e4b7cba-f4a1-5221-9b40-b3adeaf750bc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"0fcf14f9-de6c-5f14-b7e2-222e952f6aa4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5bcf1ebc-c823-5866-8643-bb3a12bd2e78","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"99f1248a-29fc-5534-8f2a-306820d31914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92a3e377-bfa8-5bcb-92d5-38bd17e970e8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2fda74-5193-58b7-9e0b-40e6129a4629","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"65080272-e93d-5ccb-a5f0-bcecaca6aae1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"44895091-401a-5a9b-b11f-a4e952ec6de2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"caffbaca-bd54-566b-921b-c2363a59a842","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"33f76ef2-b579-5b80-985a-587d2f7cbb17","slug":"background-information","fullItemName":"Background information"},"subChapters":[{"id":"2297c337-9aee-559c-aeca-bfea63bf0919","slug":"apremilast","fullItemName":"Apremilast","depth":3,"htmlHeader":"<!-- begin field 54c2c18e-917a-41cb-b8d8-a7ed00a3e8fa --><h3>What are the indications for apremilast?</h3><!-- end field 54c2c18e-917a-41cb-b8d8-a7ed00a3e8fa -->","summary":null,"htmlStringContent":"<!-- begin item b5af5eeb-6298-4eb4-863b-a7ed00a3e632 --><!-- begin field 13eeba91-b9ea-4c3a-8003-a7ed00a3e8fa --><ul><li>Apremilast is licensed for the treatment of:<ul><li><strong>Psoriatic arthritis</strong> — alone or in combination with disease modifying antirheumatic drugs (DMARDs) for adults who were intolerant to, or had an inadequate response from, another DMARD.  </li><li><strong>Chronic plaque psoriasis</strong> — moderate to severe chronic plaque psoriasis in adults who were intolerant to, had an inadequate response from, or who had a contraindication to other systemic therapies including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017a</a>]</p><!-- end field 13eeba91-b9ea-4c3a-8003-a7ed00a3e8fa --><!-- end item b5af5eeb-6298-4eb4-863b-a7ed00a3e632 -->","subChapters":[]},{"id":"f0686cd9-6495-54b4-b2af-384aef2207e0","slug":"azathioprine","fullItemName":"Azathioprine","depth":3,"htmlHeader":"<!-- begin field c6f30ef5-a358-4410-be06-9d4385083c20 --><h3>What are the indications for azathioprine?</h3><!-- end field c6f30ef5-a358-4410-be06-9d4385083c20 -->","summary":null,"htmlStringContent":"<!-- begin item 6f41917f-64c5-4914-83a3-43d8f594bd85 --><!-- begin field c446e90c-9f61-49c8-ad86-aa5707ae1f07 --><ul><li>Azathioprine is licensed for use alone, or in combination with other drugs for treatment of:<ul><li>Severe rheumatoid arthritis.</li><li>Systemic lupus erythematosus.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017b</a>]</p><!-- end field c446e90c-9f61-49c8-ad86-aa5707ae1f07 --><!-- end item 6f41917f-64c5-4914-83a3-43d8f594bd85 -->","subChapters":[]},{"id":"b93c992e-b458-52da-9b90-96bc5d8e803f","slug":"baricitinib","fullItemName":"Baricitinib","depth":3,"htmlHeader":"<!-- begin field cb080921-da82-4ae7-a5ff-a7ed00a5c8c4 --><h3>What are the indications for baricitinib?</h3><!-- end field cb080921-da82-4ae7-a5ff-a7ed00a5c8c4 -->","summary":null,"htmlStringContent":"<!-- begin item 7e8689e6-8f4f-4ef6-8456-a7ed00a5c6f4 --><!-- begin field aa1b7a84-22db-4f8c-9ef2-a7ed00a5c8c4 --><ul><li>Baricitinib is licensed for the treatment of:<ul><li><strong>Moderate to severe active rheumatoid arthritis (RA)</strong> in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD).<ul><li>It can be used as monotherapy, or in combination with methotrexate (MTX).</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017c</a>] </p><!-- end field aa1b7a84-22db-4f8c-9ef2-a7ed00a5c8c4 --><!-- end item 7e8689e6-8f4f-4ef6-8456-a7ed00a5c6f4 -->","subChapters":[]},{"id":"49d4f153-52a6-5303-b450-b114a55c6185","slug":"biologics","fullItemName":"Biologics","depth":3,"htmlHeader":"<!-- begin field 4561ec3b-e63c-4811-96f2-81c39f84f95c --><h3>What are the indications for biologics?</h3><!-- end field 4561ec3b-e63c-4811-96f2-81c39f84f95c -->","summary":null,"htmlStringContent":"<!-- begin item 7ebef8a2-d5e8-46c8-955b-bb761c401017 --><!-- begin field 6c828202-684a-4fc6-a930-e7e237aff0cc --><ul><li>The term biologics encompasses tumour necrosis factor (TNF) inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) and other agents, including abatacept, anakinra, belimumab, ixekizumab, rituximab, secukinumab, tocilizumab, and ustekinumab.</li></ul><h4>Abatacept</h4><ul><li>Abatacept is licensed, in combination with methotrexate (MTX), for the treatment of:<ul><li><strong>Moderate-to-severe active rheumatoid arthritis </strong>in adults who have had an insufficient response to other disease-modifying anti-rheumatic drugs (DMARDs) including MTX or a tumour necrosis factor (TNF) alpha inhibitor.</li><li><strong>Highly active and progressive rheumatoid arthritis</strong> in adults not previously treated with methotrexate.</li></ul></li><li>Abatacept is also licensed alone, or in combination with MTX, for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy including MTX has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017d</a>] </p><h4>Adalimumab</h4><ul><li>Adalimumab is licensed for the treatment of:<ul><li><strong>Rheumatoid arthritis</strong>.<ul><li>In combination with methotrexate for moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate has been inadequate, or the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.</li><li>As monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.</li></ul></li><li><strong>Juvenile idiopathic arthritis.</strong><ul><li>In combination with methotrexate from the age of 2 years for people who have had an inadequate response to one or more DMARDs.</li><li>As monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.</li><li>For the treatment of active enthesitis-related arthritis in people, aged 6 years and over, who have had an inadequate response to, or who are intolerant of, conventional therapy.</li></ul></li><li><strong>Axial spondyloarthritis.</strong><ul><li>Adults with severe active ankylosing spondylitis (AS) who have had an inadequate response to conventional therapy.</li><li>Adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C-reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).</li></ul></li><li><strong>Psoriatic arthritis.</strong><ul><li>Active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.</li></ul></li><li><strong>Psoriasis.</strong><ul><li>Moderate to severe chronic plaque psoriasis in adults.</li></ul></li><li><strong>Paediatric plaque psoriasis</strong>.<ul><li>Severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.</li></ul></li><li><strong>Hidradenitis supparativa.</strong><ul><li>Active moderate to severe hidradenitis suppurativa in adults and adolescents from 12 years of age with an inadequate response to conventional systemic therapy.</li></ul></li><li><strong>Crohn's disease.</strong><ul><li>Moderately to severely active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to, or have medical contraindications for such therapies.</li></ul></li><li><strong>Paediatric Crohn's disease.</strong><ul><li>Moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.</li></ul></li><li><strong>Ulcerative colitis.</strong><ul><li>Moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.</li></ul></li><li><strong>Uveitis.</strong><ul><li>Non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.</li></ul></li><li><strong>Paediatric uveitis.</strong><ul><li>Chronic non-infectious anterior uveitis in children aged 2 years and older who have had an inadequate response to, or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017e</a>] </p><h4>Anakinra</h4><ul><li>Anakinra is licensed for the treatment of:<ul><li><strong>Rheumatoid arthritis </strong>— in combination with methotrexate, in people with an inadequate response to methotrexate alone.</li><li><strong>Cryopyrin-Associated Periodic Syndromes (CAPS)</strong> — in adults and children aged 8 months and over, with a body weight of 10 kg or more.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2016a</a>]</p><h4>Belimumab</h4><ul><li>Belimumab is licensed as add-on therapy in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite standard therapy.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2016b</a>] </p><h4>Certolizumab pegol</h4><ul><li>Certolizumab pegol is licensed for the treatment of:<ul><li><strong>Rheumatoid arthritis.</strong><ul><li>In combination with methotrexate (MTX) for treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate.</li><li>As monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate.</li><li>Treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.</li></ul></li><li><strong>Axial spondyloarthritis.</strong><ul><li>Severe active ankylosing spondylitis (AS) in people who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).</li><li>Severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C-reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs.</li></ul></li><li><strong>Psoriatic arthritis.</strong><ul><li>In combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.</li><li>As monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017f</a>] </p><h4>Etanercept</h4><ul><li>Etanercept is licensed for the treatment of:<ul><li><strong>Rheumatoid arthritis</strong>.<ul><li>In combination with methotrexate (MTX) for moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate has been inadequate, or the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.</li><li>As monotherapy in case of intolerance to methotrexate or when continued treatment with MTX is inappropriate.</li></ul></li><li><strong>Juvenile idiopathic arthritis.</strong><ul><li>Polyarthritis and extended oligoarthritis in children aged 2 years or older who have had an inadequate response to, or are intolerant of, MTX.</li><li>Psoriatic arthritis in adolescents aged 12 years and over who have had an inadequate response to, or are intolerant of, MTX.</li><li>Enthesitis-related arthritis in adolescents aged 12 years and over who have had an inadequate response to, or who have proved intolerant of, conventional therapy.</li></ul></li><li><strong>Axial spondyloarthritis.</strong><ul><li>Adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.</li><li>Adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C-reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).</li></ul></li><li><strong>Psoriatic arthritis.</strong><ul><li>Active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.</li></ul></li><li><strong>Plaque psoriasis.</strong><ul><li>Moderate to severe chronic plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA).</li></ul></li><li><strong>Paediatric plaque psoriasis</strong>.<ul><li>Severe chronic plaque psoriasis in children and adolescents aged 6 years and over who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017g</a>] </p><h4>Golimumab</h4><ul><li>Golimumab is licensed for the treatment of:<ul><li><strong>Rheumatoid arthritis</strong>.<ul><li>In combination with methotrexate for moderate to severe active disease in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate has been inadequate, or the treatment of severe, active and progressive disease in adults not previously treated with methotrexate.</li></ul></li><li><strong>Axial spondyloarthritis.</strong><ul><li>Adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.</li><li>Adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).</li></ul></li><li><strong>Psoriatic arthritis.</strong><ul><li>Active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Either alone, or in combination with methotrexate.</li></ul></li><li><strong>Ulcerative colitis.</strong><ul><li>Moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017h</a>] </p><h4>Infliximab</h4><ul><li>Infliximab is licensed for the treatment of:<ul><li><strong>Rheumatoid arthritis</strong>.<ul><li>In combination with methotrexate for active disease in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate has been inadequate, or the treatment of severe, active and progressive disease in adults not previously treated with methotrexate or other DMARDs.</li></ul></li><li><strong>Ankylosing spondylitis.</strong><ul><li>Adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.</li></ul></li><li><strong>Psoriatic arthritis.</strong><ul><li>Active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Either in combination with methotrexate, or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated</li></ul></li><li><strong>Psoriasis.</strong><ul><li>Moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultra-violet A (PUVA).</li></ul></li><li><strong>Crohn's disease.</strong><ul><li>Moderately to severely active Crohn's disease, in adult patients who have not responded to a corticosteroid and/or an immunosuppressant; or who are intolerant to, or have medical contraindications for such therapies.</li><li>Fistulising, active Crohn's disease, in adult patients who have not responded to conventional treatment.</li></ul></li><li><strong>Paediatric Crohn's disease.</strong><ul><li>Moderately to severely active Crohn's disease in paediatric patients (aged 6 years and over) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications to them.</li></ul></li><li><strong>Ulcerative colitis.</strong><ul><li>Moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications to them.</li></ul></li><li><strong>Paediatric ulcerative colitis.</strong><ul><li>Severely active ulcerative colitis in children (aged 6 years and over) who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications to them.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017i</a>] </p><h4>Ixekinumab</h4><ul><li><p>Ixekizumab is licensed for the treatment of moderate to severe plaque psoriasis in adults.</p></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017j</a>] </p><h4>Rituximab</h4><ul><li>Rituximab is licensed for the treatment of:<ul><li><strong>Rheumatoid arthritis.</strong><ul><li>In combination with methotrexate for severe active rheumatoid arthritis in adults who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.</li></ul></li><li><strong>Granulomatis with polyangitis and microscopic polyangitis.</strong><ul><li>In combination with glucocorticoids for induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017k</a>] </p><h4>Secukinumab</h4><ul><li>Secukinumab is licensed for the treatment of:<ul><li>Plaque psoriasis in adults.</li><li>Psoriatic arthritis — alone or in combination with methotrexate (MTX), in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.</li><li>Ankylosing spondylitis in adults who have responded inadequately to conventional therapy.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017l</a>] </p><h4>Tocilizumab</h4><ul><li>Tocilizumab is licensed for treatment of:<ul><li><strong>Rheumatoid arthritis.</strong><ul><li>Severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with methotrexate (MTX).</li><li>Moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017m</a>]</p><h4>Ustekinumab</h4><ul><li>Ustekinumab is licensed for the treatment of adults with moderately to severely active Crohn's disease who have not responded to, or were intolerant to, either conventional therapy or a tumour necrosis factor (TNF) alpha antagonist, or in whom other therapies are contraindicated.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2016c</a>] </p><!-- end field 6c828202-684a-4fc6-a930-e7e237aff0cc --><!-- end item 7ebef8a2-d5e8-46c8-955b-bb761c401017 -->","subChapters":[]},{"id":"673f9987-f7a6-5d89-858f-c7ea7ecf6186","slug":"ciclosporin","fullItemName":"Ciclosporin","depth":3,"htmlHeader":"<!-- begin field c95a40fe-9e30-4342-88be-a76700ac6b05 --><h3>What are the indications for ciclosporin?</h3><!-- end field c95a40fe-9e30-4342-88be-a76700ac6b05 -->","summary":null,"htmlStringContent":"<!-- begin item 433926b8-a3fb-4707-9830-a76700ac6970 --><!-- begin field f47b1e72-b76c-4661-8acf-a76700ac6b05 --><ul><li>Ciclosporin is licensed for the treatment of:<ul><li><strong>Rheumatoid arthritis </strong>— severe active rheumatoid arthritis.</li><li><strong>Psoriasis </strong>— severe psoriasis in people for whom conventional therapy is inappropriate or ineffective.</li><li><strong>Atopic dermatitis </strong>— severe atopic dermatitis when systemic therapy is required.</li><li><strong>Nephrotic syndrome </strong>— steroid-dependent and steroid-resistant nephrotic syndrome, due to primary glomerular diseases such as minimal change nephropathy, focal and segmental glomerulosclerosis, or membranous glomerulonephritis.</li><li><strong>Endogenous uveitis.</strong><ul><li>Sight-threatening intermediate or posterior uveitis of non-infectious aetiology in people for whom conventional therapy has failed or caused unacceptable side effects.</li><li>Behçet uveitis with repeated inflammatory attacks involving the retina in patients without neurological manifestations.</li></ul></li></ul></li><li>Ciclosporin also has an important role in organ and tissue transplantation, however these indications are outwith the scope of this topic. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017n</a>] </p><!-- end field f47b1e72-b76c-4661-8acf-a76700ac6b05 --><!-- end item 433926b8-a3fb-4707-9830-a76700ac6970 -->","subChapters":[]},{"id":"33b2e0a3-8d2c-574e-b865-103d27cb57d2","slug":"cyclophosphamide","fullItemName":"Cyclophosphamide","depth":3,"htmlHeader":"<!-- begin field 10c12fa4-53ef-4a1f-95e4-a76700ac84dd --><h3>What are indications for cyclophosphamide?</h3><!-- end field 10c12fa4-53ef-4a1f-95e4-a76700ac84dd -->","summary":null,"htmlStringContent":"<!-- begin item c2f5c253-8d8d-4cc7-97fe-a76700ac8384 --><!-- begin field e1e82730-7128-426d-b583-a76700ac84dd --><ul><li>Cyclophosphamide is indicated in:<ul><li><strong>Severe systemic rheumatoid arthritis</strong> and other connective tissue disorders, especially with vasculitis.</li></ul></li><li>Cyclophosphamide has an important role as an antineoplastic medicine, however these indications are outwith the scope of this topic.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BNF 73, 2017</a>]</p><!-- end field e1e82730-7128-426d-b583-a76700ac84dd --><!-- end item c2f5c253-8d8d-4cc7-97fe-a76700ac8384 -->","subChapters":[]},{"id":"16d1a6e9-778f-5330-a1be-da6045466b92","slug":"gold-intramuscular","fullItemName":"Gold - intramuscular","depth":3,"htmlHeader":"<!-- begin field 6dc56ecb-f3dc-4f6a-8ad7-a76700ac956f --><h3>What are the indications for gold – intramuscular?</h3><!-- end field 6dc56ecb-f3dc-4f6a-8ad7-a76700ac956f -->","summary":null,"htmlStringContent":"<!-- begin item dbf7a230-1d48-4f40-95c7-a76700ac940a --><!-- begin field 8efa2e07-1946-4709-a0e4-a76700ac956f --><ul><li>Intramuscular gold (sodium aurothiomalate) is licensed for the treatment of:<ul><li>Progressive rheumatoid arthritis. </li><li>Juvenile chronic arthritis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2013</a>] </p><!-- end field 8efa2e07-1946-4709-a0e4-a76700ac956f --><!-- end item dbf7a230-1d48-4f40-95c7-a76700ac940a -->","subChapters":[]},{"id":"612bdc30-cb84-55d9-ada0-3627a4fc49be","slug":"hydroxychloroquine","fullItemName":"Hydroxychloroquine","depth":3,"htmlHeader":"<!-- begin field df5059c7-373f-4d2b-818a-a76700acae4c --><h3>What are the indications for hydroxychloroquine?</h3><!-- end field df5059c7-373f-4d2b-818a-a76700acae4c -->","summary":null,"htmlStringContent":"<!-- begin item 61d2d048-8479-462d-af2c-a76700acace5 --><!-- begin field 090ccb79-32bc-41c2-9cfb-a76700acae4c --><ul><li>Hydroxychloroquine is licensed for the treatment of:<ul><li>Rheumatoid arthritis, discoid and systemic lupus erythematosus in adults.</li><li>Juvenile idiopathic arthritis (in combination with other therapies), discoid and systemic lupus erythematosus in children.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017o</a>]</p><!-- end field 090ccb79-32bc-41c2-9cfb-a76700acae4c --><!-- end item 61d2d048-8479-462d-af2c-a76700acace5 -->","subChapters":[]},{"id":"9b1c115a-8e2c-590b-9c50-151817dcf249","slug":"leflunomide","fullItemName":"Leflunomide","depth":3,"htmlHeader":"<!-- begin field c17d6a4f-9123-4c73-9059-a76700acc2c4 --><h3>What are the indications for leflunomide?</h3><!-- end field c17d6a4f-9123-4c73-9059-a76700acc2c4 -->","summary":null,"htmlStringContent":"<!-- begin item b25c5f22-5a8b-41bc-8f6b-a76700acc104 --><!-- begin field ad4f86a7-6ddc-45e4-9de6-a76700acc2c4 --><ul><li>Leflunomide is licensed for the treatment of adults with:<ul><li>Rheumatoid arthritis</li><li>Psoriatic arthritis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017p</a>]</p><!-- end field ad4f86a7-6ddc-45e4-9de6-a76700acc2c4 --><!-- end item b25c5f22-5a8b-41bc-8f6b-a76700acc104 -->","subChapters":[]},{"id":"8a9f3000-efdb-5335-9c9c-066626e7ca10","slug":"methotrexate","fullItemName":"Methotrexate","depth":3,"htmlHeader":"<!-- begin field 81a64c97-b55b-49f0-a58f-a76700acd47e --><h3>What are the indications for methotrexate?</h3><!-- end field 81a64c97-b55b-49f0-a58f-a76700acd47e -->","summary":null,"htmlStringContent":"<!-- begin item 4c224666-029d-4e54-b0ec-a76700acd30d --><!-- begin field 8dfc5918-5105-43fd-b153-a76700acd47e --><ul><li>Methotrexate is licensed for the treatment of:<ul><li>Severe, active, classical or definite rheumatoid arthritis in people who are unresponsive or intolerant to conventional therapy.</li><li>Severe, uncontrolled psoriasis which is not responsive to other therapy.</li></ul></li><li>Methotrexate is also used in a number of neoplastic conditions, but these indications are outwith the scope of this topic.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2014</a>] </p><!-- end field 8dfc5918-5105-43fd-b153-a76700acd47e --><!-- end item 4c224666-029d-4e54-b0ec-a76700acd30d -->","subChapters":[]},{"id":"9623b7e1-15cb-5a82-b267-681e087fcaa8","slug":"mycophenolate-mofetil-mmf","fullItemName":"Mycophenolate mofetil (MMF)","depth":3,"htmlHeader":"<!-- begin field 660949f1-d386-47d0-b689-a76700acf3c2 --><h3>What are the indications for mycophenolate mofetil (MMF)?</h3><!-- end field 660949f1-d386-47d0-b689-a76700acf3c2 -->","summary":null,"htmlStringContent":"<!-- begin item 6bc905d7-6bf2-44ed-98df-a76700acefea --><!-- begin field 64abdd17-f147-4eb4-900b-a76700acf3c2 --><ul><li>The use of mycophenolate mofetil (MMF) in treatment of systemic lupus erythematosus and vasculitic disorders is unlicensed.<ul></ul></li><li>MMF also has an important role in organ and tissue transplantation, but these indications are outwith the scope of this topic.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BNF 73, 2017</a>]</p><!-- end field 64abdd17-f147-4eb4-900b-a76700acf3c2 --><!-- end item 6bc905d7-6bf2-44ed-98df-a76700acefea -->","subChapters":[]},{"id":"7421ea3d-5e3b-511e-af2c-c1cc763af64a","slug":"penicillamine","fullItemName":"Penicillamine","depth":3,"htmlHeader":"<!-- begin field 1c8e6e44-6d20-4147-a0d7-a76700ad0c07 --><h3>What are the indications for penicillamine?</h3><!-- end field 1c8e6e44-6d20-4147-a0d7-a76700ad0c07 -->","summary":null,"htmlStringContent":"<!-- begin item 6d565359-2096-4930-8487-a76700ad0a81 --><!-- begin field 0471b6b1-ed4c-4c75-a200-a76700ad0c07 --><ul><li>Penicillamine is licensed for the treatment of:<ul><li>Severe active rheumatoid arthritis (including juvenile forms).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017q</a>] </p><!-- end field 0471b6b1-ed4c-4c75-a200-a76700ad0c07 --><!-- end item 6d565359-2096-4930-8487-a76700ad0a81 -->","subChapters":[]},{"id":"4d2a4794-ee5a-5fb8-a757-7f8bdac2ef41","slug":"sulfasalazine","fullItemName":"Sulfasalazine","depth":3,"htmlHeader":"<!-- begin field 8be7c85a-057d-47ac-9b1c-a76700ad3163 --><h3>What are the indications for sulfasalazine?</h3><!-- end field 8be7c85a-057d-47ac-9b1c-a76700ad3163 -->","summary":null,"htmlStringContent":"<!-- begin item 21154317-1981-435f-8aeb-a76700ad2fb6 --><!-- begin field 2f6bba56-c315-4d5c-ac0e-a76700ad3163 --><ul><li>Sulfasalazine is licensed for the treatment of:<ul><li>Rheumatoid arthritis which has failed to respond to nonsteroidal anti-inflammatory drugs (NSAIDs).</li><li>Ulcerative colitis, and Crohn's disease.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI Medicines Compendium, 2014</a>]</p><!-- end field 2f6bba56-c315-4d5c-ac0e-a76700ad3163 --><!-- end item 21154317-1981-435f-8aeb-a76700ad2fb6 -->","subChapters":[]},{"id":"1fa05816-92fc-57fe-9b27-7961158025be","slug":"tacrolimus","fullItemName":"Tacrolimus","depth":3,"htmlHeader":"<!-- begin field 435ca5b0-5f2e-45d0-8493-a7ee00ac31aa --><h3>What are the indications for tacrolimus?</h3><!-- end field 435ca5b0-5f2e-45d0-8493-a7ee00ac31aa -->","summary":null,"htmlStringContent":"<!-- begin item c5dd044b-41b5-42cd-b116-a7ee00ac3009 --><!-- begin field 9cfb6ba8-890c-4580-9dca-a7ee00ac31aa --><ul><li>Treatment of rheumatological conditions is an off-license indication for tacrolimus.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BNF 73, 2017</a>]</p><!-- end field 9cfb6ba8-890c-4580-9dca-a7ee00ac31aa --><!-- end item c5dd044b-41b5-42cd-b116-a7ee00ac3009 -->","subChapters":[]},{"id":"af6a2c44-c6d1-59b8-acfa-8db0344b5286","slug":"tofacitinib","fullItemName":"Tofacitinib","depth":3,"htmlHeader":"<!-- begin field 746fd14d-2ead-4f6f-b2c4-a7ed00a5aa14 --><h3>What are the indications for tofacitinib?</h3><!-- end field 746fd14d-2ead-4f6f-b2c4-a7ed00a5aa14 -->","summary":null,"htmlStringContent":"<!-- begin item 83c8203b-f7cf-4575-b8c5-a7ed00a5a860 --><!-- begin field 9363ffd6-f5a1-4032-b4de-a7ed00a5aa14 --><ul><li>Tofacitinib is licensed for the treatment of:<ul><li><strong>Severe active rheumatoid arthritis (RA)</strong> in adults, in combination with methotrexate (MTX) who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).<ul><li>It can be given as monotherapy if MTX is unsuitable, or inappropriate.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017r</a>] </p><!-- end field 9363ffd6-f5a1-4032-b4de-a7ed00a5aa14 --><!-- end item 83c8203b-f7cf-4575-b8c5-a7ed00a5a860 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}